Long-term disease-specific functioning among prostate cancer survivors and noncancer controls in the prostate, lung, colorectal, and ovarian cancer screening trial

Journal of Clinical Oncology

Volumn 30, Issue 22, 2012, Pages 2768-2775

  Taylor, Kathryn L ^a   Luta, George ^a   Miller, Anthony B ^b   Church, Timothy R ^c   Kelly, Scott P ^a   Muenz, Larry R ^d   Davis, Kimberly M ^a   Dawson, David L ^a   Edmond, Sara ^a   Reding, Douglas ^e   Mabie, Jerome E ^f   Riley, Thomas L ^f  

^a GEORGETOWN UNIVERSITY   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF MINNESOTA DULUTH   (United States)

^d Larry R Muenz and Associates   (United States)

^e MARSHFIELD CLINIC   (United States)

^f INFORMATION MANAGEMENT SERVICES INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER SCREENING; CANCER SURVIVOR; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED STUDY; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; OVARY CANCER; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RACE DIFFERENCE; SEXUAL FUNCTION; TELECONSULTATION; TREATMENT OUTCOME; URINARY TRACT FUNCTION;

AGED; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; LINEAR MODELS; LUNG NEOPLASMS; MALE; MIDDLE AGED; OVARIAN NEOPLASMS; PROSTATIC NEOPLASMS; SURVIVORS;

EID: 84864573102     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.41.2767     Document Type: Article

References (47)

1. Brawley OW, Ankerst DP, Thompson IM: Screening for prostate cancer. CA Cancer J Clin 59:264-273, 2009
2. Schröder FH, Hugosson J, Roobol MJ, et al: Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360:1320-1328, 2009
3. Schröder FH, Hugosson J, Roobol MJ, et al: Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 366:981-990, 2012
4. Andriole GL, Crawford ED, Grubb RL 3rd, et al: Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360:1310-1319, 2009
5. Andriole GL, Crawford ED, Grubb RL III, et al: Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality results after 13 years of follow-up. J Natl Cancer Inst 104:125-132, 2012
6. Bill-Axelson A, Holmberg L, Ruutu M, et al: Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 352:1977-1984, 2005 (Pubitemid 40638368)
7. Wilt TJ, Brawer MK, Barry MJ, et al: The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): Design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer. Contemp Clin Trials 30:81-87, 2009
8. Djulbegovic M, Beyth RJ, Neuberger MM, et al: Screening for prostate cancer: Systematic review and meta-analysis of randomised controlled trials. BMJ 341:c4543, 2010
9. Ilic D, O'Connor D, Green S, et al: Screening for prostate cancer: An updated Cochrane systematic review. BJU Int 107:882-891, 2011
10. US Preventive Services Task Force: Screening for prostate cancer, topic page. http://www.uspreventiveservicestaskforce.org/uspstf/uspsprca.htm
11. Barry MJ, Gallagher PM, Skinner JS, et al: Adverse effects of robotic-assisted laparoscopic versus open retropubic radical prostatectomy among a nationwide random sample of medicare-age men. J Clin Oncol 30:513-518, 2012
12. Lin GA, Aaronson DS, Knight SJ, et al: Patient decision aids for prostate cancer treatment: A systematic review of the literature. CA Cancer J Clin 59:379-390, 2009
13. Zafar SY, Alexander SC, Weinfurt KP, et al: Decision making and quality of life in the treatment of cancer: A review. Support Care Cancer 17:117-127, 2009
14. Zeliadt SB, Ramsey SD, Penson DF, et al: Why do men choose one treatment over another? A review of patient decision making for localized prostate cancer. Cancer 106:1865-1874, 2006 (Pubitemid 43673200)
15. Bacon CG, Giovannucci E, Testa M, et al: The impact of cancer treatment on quality of life outcomes for patients with localized prostate cancer. J Urol 166:1804-1810, 2001
16. Hoffman RM, Gilliland FD, Penson DF, et al: Cross-sectional and longitudinal comparisons of health-related quality of life between patients with prostate carcinoma and matched controls. Cancer 101:2011-2019, 2004 (Pubitemid 39425377)
17. Miller DC, Sanda MG, Dunn RL, et al: Long-term outcomes among localized prostate cancer survivors: Health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy. J Clin Oncol 23:2772-2780, 2005 (Pubitemid 46179467)
18. Mols F, Korfage IJ, Vingerhoets AJ, et al: Bowel, urinary, and sexual problems among long-term prostate cancer survivors: A population-based study. Int J Radiat Oncol Biol Phys 73:30-38, 2009
19. Carlsson S, Aus G, Bergdahl S, et al: The excess burden of side-effects from treatment in men allocated to screening for prostate cancer. The Göteborg randomised population-based prostate cancer screening trial. Eur J Cancer 47:545-553, 2011
20. Essink-Bot ML, Korfage IJ, De Koning HJ: Including the quality-of-life effects in the evaluation of prostate cancer screening: Expert opinions revisited? BJU Int 92:101-105, 2003 (suppl 2)
21. Hoffman RM, Stone SN, Espey D, et al: Differences between men with screening-detected versus clinically diagnosed prostate cancers in the USA. BMC Cancer 5:27, 2005
22. Korfage IJ, Essink-Bot ML, Borsboom GJ, et al: Five-year follow-up of health-related quality of life after primary treatment of localized prostate cancer. Int J Cancer 116:291-296, 2005 (Pubitemid 40967268)
23. Litwin MS, Sadetsky N, Pasta DJ, et al: Bowel function and bother after treatment for early stage prostate cancer: A longitudinal quality of life analysis from CaPSURE. J Urol 172:515-519, 2004 (Pubitemid 38900193)
24. Penson DF, McLerran D, Feng Z, et al: 5-year urinary and sexual outcomes after radical prostatectomy: Results from the prostate cancer outcomes study. J Urol 173:1701-1705, 2005 (Pubitemid 40524809)
25. Potosky AL, Davis WW, Hoffman RM, et al: Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: The prostate cancer outcomes study. J Natl Cancer Inst 96:1358-1367, 2004 (Pubitemid 39406169)
26. Sanda MG, Dunn RL, Michalski J, et al: Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 358:1250-1261, 2008 (Pubitemid 351439226)
27. Huang GJ, Sadetsky N, Penson DF: Health related quality of life for men treated for localized prostate cancer with long-term followup. J Urol 183:2206-2212, 2010
28. Mols F, van de Poll-Franse LV, Vingerhoets AJ, et al: Long-term quality of life among Dutch prostate cancer survivors: Results of a population-based study. Cancer 107:2186-2196, 2006 (Pubitemid 44665653)
29. Andriole GL, Levin DL, Crawford ED, et al: Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: Findings from the initial screening round of a randomized trial. J Natl Cancer Inst 97:433-438, 2005 (Pubitemid 40528606)
30. Prorok PC, Andriole GL, Bresalier RS, et al: Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials 21:273S-309S, 2000
31. Wei JT, Dunn RL, Litwin MS, et al: Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 56:899-905, 2000
32. Horvitz DG, Thompson DJ: A generalization of sampling without replacement from a finite universe. J Am Stat Assoc 47:663-685, 1952
33. Austin PC: The relative ability of different propensity score methods to balance measured covariates between treated and untreated subjects in observational studies. Med Decis Making 29:661-677, 2009
34. D'Agostino RB Jr: Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 17:2265-2281, 1998
35. Vandenbroucke JP, von Elm E, Altman DG, et al: Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and elaboration. Ann Intern Med 147:W163-W194, 2007 (Pubitemid 351664503)
36. Committee on Cancer Survivorship: Improving Care and Quality of Life, Institute of Medicine and National Research Council: From Cancer Patient to Cancer Survivor: Lost in Transition. Washington, DC, National Academies Press, 2005, pp 187-191
37. Bacon CG, Giovannucci E, Testa M, et al: The association of treatment-related symptoms with quality-of-life outcomes for localized prostate carcinoma patients. Cancer 94:862-871, 2002 (Pubitemid 34132318)
38. Madalinska JB, Essink-Bot ML, de Koning HJ, et al: Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer. J Clin Oncol 19:1619-1628, 2001 (Pubitemid 32230861)
39. Madalinska JB, Essink-Bot ML, de Koning HJ, et al: Health-related quality of life in patients with screen-detected versus clinically diagnosed prostate cancer preceding primary treatment. Prostate 46:87-97, 2001
40. Lips I, Dehnad H, Kruger AB, et al: Health-related quality of life in patients with locally advanced prostate cancer after 76 Gy intensity-modulated radiotherapy vs. 70 Gy conformal radiotherapy in a prospective and longitudinal study. Int J Radiat Oncol Biol Phys 69:656-661, 2007 (Pubitemid 47418401)
41. Namiki S, Ishidoya S, Tochigi T, et al: Health-related quality of life after intensity modulated radiation therapy for localized prostate cancer: Comparison with conventional and conformal radiotherapy. Jpn J Clin Oncol 36:224-230, 2006 (Pubitemid 43997322)
42. Namiki S, Ishidoya S, Ito A, et al: Five-year follow-up of health-related quality of life after intensity-modulated radiation therapy for prostate cancer. Jpn J Clin Oncol 39:732-738, 2009
43. Pinsky PF, Miller A, Kramer BS, et al: Evidence of a healthy volunteer effect in the prostate, lung, colorectal, and ovarian cancer screening trial. Am J Epidemiol 165:874-881, 2007 (Pubitemid 46536660)
44. Wei JT, Dunn RL, Sandler HM, et al: Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol 20:557-566, 2002 (Pubitemid 34072540)
45. Potosky AL, Legler J, Albertsen PC, et al: Health outcomes after prostatectomy or radiotherapy for prostate cancer: Results from the Prostate Cancer Outcomes Study. J Natl Cancer Inst 92:1582-1592, 2000
46. Shen X, Keith SW, Mishra MV, et al: The impact of brachytherapy on prostate cancer-specific mortality for definitive radiation therapy of high-grade prostate cancer: A population-based analysis. Int J Radiat Oncol Biol Phys 10.1016/j.ijrobp.2011.09.055 [epub ahead of print on January 21, 2012]
47. Rosenbaum PR, Rubin DB: The central role of the propensity score in observational studies for causal effects. Biometrika 70:41-55, 1983